位置:成果数据库 > 期刊 > 期刊详情页
左乙拉西坦治疗难治性癫痫48例的临床研究
  • ISSN号:1008-0678
  • 期刊名称:《中国临床神经科学》
  • 时间:0
  • 分类:R742.1[医药卫生—神经病学与精神病学;医药卫生—临床医学]
  • 作者机构:[1]广州医学院第二附属医院神经内科,广州医学院神经科学研究所,广东省重点实验室,神经遗传与离子通道省部共建教育部重点实验室,510260
  • 相关基金:国家自然科学基金资助项目(编号:30700247);广州市市属高校科技计划项目(编号:61021);广州医学院第二附属医院科研立项(2007-5)
中文摘要:

目的:探讨左乙拉西坦(Lev)添加剂量治疗难治性癫痫的疗效和安全性。方法:采用开放性自身对照方法,对48例(儿童23例,成人25例)难治性癫痫患者进行Lev添加治疗,并随访1年以上,收集治疗后患者发作频率变化、无发作情况、不良反应以及退出原因。结果:Lev治疗难治性癫痫总有效率为64.58%,成人有效率高于儿童,对部分性癫痫综合征有效率高;3、6和12个月无发作率分别为6.25%、18.75%和16.67%,保留率为81.25%、56.25%和43.75%。总不良反应发生率为39.58%,无严重不良反应,退出的最主要原因为对疗效欠满意。结论:LEV是一种安全有效的难治性癫痫治疗药物,对部分性和全面性癫痫发作均有效。

英文摘要:

Aim: To evaluate the efficacy and safety of levetiracetam (Lev) as adjunctive therapy for refractory epilepsy. Methods: An open-label, own control study were explored for 48 cases refractory epilepsy patients (23 children and 25 adults). Patients were administered the maximum-effective Lev dose as adjunctive therapy and followed up for at least one year. The clinical data including seizure frequency, adverse effects and exit reasons were collected. Results: 64.58% patients had more than 50% reduction in seizure frequency, and the ratio in adults was higher than children' s. 6.25%, 18.75%, 16.67% patients got seizure free in 3 months, 6 months and 1 year, and the retention rate was 81.25%, 56.25%, 43.75% respectively. 39.58% patients reported one or more adverse effects, but no serious adverse effect appeared. The most common exit reason was not satisfying with the efficacy. Conclusion: Lev is effective and safe as adjunctive therapy for refractory epilepsy, and it is useful for both partial epilepsy and generalized epilepsy.

同期刊论文项目
同项目期刊论文
期刊信息
  • 《中国临床神经科学》
  • 中国科技核心期刊
  • 主管单位:教育部
  • 主办单位:复旦大学神经病学研究 复旦大学附属华山医院
  • 主编:蒋雨平
  • 地址:上海乌鲁木齐中路12号
  • 邮编:200040
  • 邮箱:cjcn1993@hotmail.com
  • 电话:021-62490808
  • 国际标准刊号:ISSN:1008-0678
  • 国内统一刊号:ISSN:31-1752/R
  • 邮发代号:4-602
  • 获奖情况:
  • 国内外数据库收录:
  • 被引量:8220